PNNL

Abstract

This paper is part two of a three-part series investigating annual effective doses to residents of the United States from intakes of ubiquitous radionuclides, including radionuclides occurring naturally, radionuclides whose concentrations are technologically enhanced, and anthropogenic radionuclides. This series of papers explicitly excludes intakes from inhaling 222Rn, 220Rn, and their short-lived decay products; it also excludes intakes of radionuclides in occupational and medical settings. Part one reviewed, summarized, characterized, and grouped all published and some unpublished data for U.S. residents on ubiquitous radionuclide concentrations in tissues and organs. Assumptions about equilibrium with long-lived parents are made for the 28 other radionuclides in these series lacking data. This paper describes the methods developed to group the collected data into source regions described in the Radiation Dose Assessment Resource (RADAR) dosimetric methodology. Methods for converting the various units of data published over 50 years into a standard form are developed and described. Often, meaningful values of uncertainty of measurements were not published so that variability in data sets is confounded with measurement uncertainty. A description of the methods developed to estimate variability is included in this paper. The data described in part one are grouped by gender and age to match the RADAR dosimetric phantoms. Within these phantoms, concentration values are grouped into source tissue regions by radionuclide, and they are imputed for source regions lacking tissue data. Radionuclide concentrations are then imputed for other phantoms’ source regions with missing concentration values, and the uncertainties of the imputed values are increased. The content concentrations of hollow organs are calculated, and activities are apportioned to the bone source regions using assumptions about each radionuclide’s bone-seeking behavior. The data sets are then ready to be used to estimate equivalent doses to target tissues from these source regions. The target tissues are then mapped to lists of tissues with International Commission on Radiation Protection (ICRP) tissue weighting factors, or they are mapped to surrogate tissue regions when there is no direct match. Effective doses, using ICRP tissue weighting factors recommended in 1977, 1990, and 2007, are calculated from tissue and organ equivalent doses.